Aggregate Biosciences
180 Varick St.
New York, NY 10014

W Vallen Graham
T 312-752-7742
www.aggregatebio.com
vallen@agg.bio

INDUSTRY: Biotech

MANAGEMENT:
W Vallen Graham, PhD
Founder, CEO

Manija Kazmi, M.S.
Founder, Ops and Outreach

Sharon Blaettler, PhD
Founder, Drug Discovery

SCIENTIFIC ADVISORY BOARD:
Thomas P. Sakmar, MD:
Founder; Richard M. & Isabel P. Furlaud Professor; Physician-Scientist, Rockefeller University

Ronald Parchem, PhD:
Founder; Professor of Molecular and Cellular Biology, Baylor College of Medicine

Mickey Urdea, PhD:
Seasoned Industry Leader: Partner, Halteres Associates
Previously: Chiron, Bayer, and Tethys

Brian Petkov, PhD:
Computational Physicist: CEO, Junction Bio
Previously: Redesign Science

FUNDING TO DATE:
$10K founder-funded
$325K SBIR Phase I (Score: 20)

FINANCING SOUGHT:
$2M Seed
IP, Proof-of-concept, Operating costs

IP (SECURING): Foundational patents for CLAMP platform, with exclusive rights under negotiation with Rockefeller University

LEGAL: WSGR, Wiggin LLP

ACCOUNTING: Shay CPA

Business Description / Company Background:
Aggregate Biosciences is redefining amyloid disease treatment by recognizing that not all amyloid protofibrils are alike—distinct morphotypes drive different aspects of disease pathology. Our proprietary precision platform is the first to identify, isolate, and selectively target the toxic morphotypes responsible for disease progression. This approach moves beyond "one-size-fits-all" treatments, enabling rational, structure-guided therapeutic design and paving the way for safer, more effective interventions. Aggregate Biosciences is the first company built entirely around morphotype targeting—bringing structural precision to a field long dominated by blind, non-specific approaches. The company was founded through scientific collaboration between four academic co-founders and seasoned industry leaders, united by a shared mission to translate a pioneering Rockefeller University discovery into a platform that can transform the treatment of amyloid diseases.

Market Opportunity / Unmet Need:
Existing amyloid therapies lack morphotype selectivity, leading to inconsistent outcomes and unnecessary risk. No current tools can isolate and characterize toxic protofibrils while preserving structural diversity. Aggregate Biosciences fills this gap with a precision platform to guide next-gen antibody therapies and diagnostics. The addressable market exceeds $20B globally, with Alzheimer's alone affecting 6M in the U.S. and 55M worldwide—numbers expected to double by 2050.

Products:
Our first product is a precision monoclonal antibody for Alzheimer's disease, with an opportunity to develop a complementary diagnostic to guide treatment. We're building a scalable platform to enable patient profiling and biomarker development across the broader amyloid disease market.

Key Milestones:
We've completed two preclinical proof-of-concept studies in animal models, validating our ability to generate in vivo data supporting morphotype-specific targeting. Built on deep academic–industry collaborations at Rockefeller University, our platform is positioned to drive the next generation of amyloid therapeutics. We anticipate nominating a lead candidate in early 2026, with first-in-human trials by late 2027 and an FDA submission projected by 2029, aligning with our anticipated commercial launch.

CLAMP Technology: Our Chaperone-Like Amyloid Modulating Proteins (CLAMPs) act as molecular scalpels—precisely isolating disease-driving amyloid morphotypes to enable structural characterization, morphotype mapping, and targeted therapeutic development.

Competition / Competitive Advantage / Customer Benefits:
Unlike current Alzheimer's therapies such as Aduhelm and Leqembi—and most preclinical candidates—our approach is not blind to amyloid structure. These treatments lack conformer selectivity, contributing to modest efficacy and safety concerns. In contrast, Aggregate Biosciences' precision platform is the first to dissect and leverage the structural diversity of amyloid protofibrils, enabling the development of safer, more effective, and truly targeted therapies.

Financial Forecast:
Forecasted Deal Terms: pharma partnership with $20–50M upfront, $150–250M in milestones, and 5–10% royalties. Projected exit valuation: $1–2B.

in (000's)	1st Yr.	2nd Yr.	3rd Yr.	4th Yr.	5th Yr.
Revenue:	$0	$0	$0	$30,000	$50,000
Gross Profit:	$0	$0	$0	$28,500	$48,000
Gross Margin:	–	–	–	95%	96%
Operating Costs*:	$2,000	$5,000	$8,000	$9,000	$10,000

**Operating Costs include R&D, G&A, and capital expenditures*